Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
A Censuswide survey of 1,000 UK dieters, commissioned by nutrition brand PortionIQ, found that 29% of those using GLP-1 medications for two years or more lacked confidence in their knowledge of essential nutrients, compared with 12% of those in their first month. Only 57% of long-term users believed they were meeting their nutrient needs, against 81% of new users. With appetite suppression reducing total intake, nutrient density and protein adequacy become determinants of whether weight loss preserves or erodes lean mass and metabolic function.
Oxford Healthspan has released Primeadine GF Spermidine Powder, a mixable gluten-free formulation delivering 1 mg of whole-food spermidine per serving from broken cell wall chlorella, with nobiletin from Shikuwasa citrus peel and curcumin. Spermidine is studied for its role in autophagy, the cellular recycling process that declines with age. The powder format addresses adherence by allowing the dose to be added to food or beverages rather than taken as a tablet.
In the REMAIN-1 pivotal cohort (N=308), a single endoscopic duodenal mucosal resurfacing procedure limited weight regain after tirzepatide discontinuation, with participants retaining roughly 80% of their drug-induced weight loss at six months versus 67% for sham. Mean regain was 5.1% versus 8.2%, and post hoc analysis indicated a dose-dependent effect, with ablation lengths of 20 cm or greater associated with 3.8% regain. The approach targets the durability problem that currently limits incretin-based weight loss as a long-term metabolic strategy.
In aging mice, bone marrow fat cells secrete DPP4 and other factors that activate the cGAS–STING pathway in marrow macrophages, producing chronic inflammatory signaling that suppresses bone formation and lowers NAD⁺ in osteoblast progenitors. Silencing STING specifically in macrophages between 12 and 18 months preserved bone density and architecture, increased new bone deposition, and reduced marrow fat accumulation. The work positions innate immune sensing of displaced DNA as an upstream driver of age-related skeletal decline rather than a bystander.
Digbi Health has extended its genomic and gut microbiome platform to menopause care, combining hormone replacement therapy, GLP-1 prescribing, and metabolic and gastrointestinal management under a single clinical team. The rationale rests on member data showing 75% of women aged 40 to 60 already carry an obesity, cardiometabolic or gastrointestinal diagnosis. Separately released IBS outcomes from nearly 16,000 members show symptom improvement at 12 weeks, though the analysis lacks a control group and does not specify the measurement scale.
Kailera Therapeutics has completed enrollment of roughly 4,900 participants across three Phase 3 trials of ribupatide, a once-weekly injection activating both GLP-1 and GIP receptors, with topline data expected mid-2028. One trial includes an open-label semaglutide 2.4 mg comparator arm in adults with a BMI of 35 or higher, making it a direct test against the current standard rather than placebo alone. No efficacy or safety data have been released.
Digbi Health has extended its precision telehealth platform to all 50 states, combining genetic, gut microbiome, blood biomarker and continuous glucose data into individualized metabolic care plans that may include GLP-1 medications or hormone replacement. Peer-reviewed analysis across seven self-insured employers reported a $3,012 annual reduction in medical spend per member. The model positions multi-signal personalization — rather than single-drug prescribing — as the organizing principle of metabolic care at employer scale.
Chronic high-fat feeding in rats imprinted a persistent senescence-like state on the liver's regenerative cell population, marked by mitochondrial dysfunction, oxidative stress, inflammatory secretion, and diminished proliferative capacity after injury. The defect persisted in organoids cultured for three passages outside the original metabolic environment, indicating the cells retained the program rather than merely responding to their surroundings. Mitochondria-targeted antioxidant treatment partially restored regenerative function, identifying mitochondrial failure as a modifiable component.
In a 16-week single-arm trial of 25 adults with type 2 diabetes, an ad libitum low-fat plant-based diet produced a spontaneous 346 kcal/day reduction in intake, 6 kg of weight loss, a 33% drop in liver fat, and substantial declines in visceral fat, fasting glucose, insulin, and LDL cholesterol. Skin advanced glycation end-products also fell, and several participants reduced or discontinued metformin. The absence of a control group and reliance on self-reported intake limit causal interpretation, but the metabolic shifts align with ectopic fat as a driver of insulin resistance.
In a transgenic mouse model of Alzheimer's disease, sleeve gastrectomy performed early in life reduced fat mass, improved insulin sensitivity, and lowered cortical amyloid burden and glial activation — effects that occurred independently of reduced caloric intake. Under continued Western-diet feeding, the procedure also reduced frailty and restored spatial memory, implicating a brain insulin signaling–autophagy axis as the mechanistic link between peripheral metabolic correction and neurodegenerative pathology.
In a question-and-answer episode, Peter Attia revisits his positions on fasting, ketogenic diets, metformin, rapamycin, whole-body MRI screening, and exercise, describing how each has shifted as evidence accumulated. He frames intellectual flexibility — holding strong convictions loosely — as a defining trait of rigorous scientists. The relevance to longevity practice lies in treating interventions as provisional hypotheses subject to revision rather than fixed commitments.
Tiny Health raised a $33m Series B to expand shotgun metagenomic microbiome testing from infants to adults, with adult samples now exceeding pediatric volume. Its strongest evidence is a 2025 randomized controlled trial reporting an 83% reduction in the odds of infant eczema following targeted microbiome intervention. The company acknowledges there is no universal definition of a healthy adult microbiome and that its new longevity-oriented scores have not yet been shown to predict health outcomes.